Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms

NCT01059383 is registered in ClinicalTrials.gov with Vecta Ltd. as lead sponsor.

NCT NCT01059383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01059383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms
Lead sponsor
Vecta Ltd.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2009
Completion date
June 30, 2011
Enrollment
52 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal reflux